Adjuvanted Influenza Vaccine in Stem Cell Transplant

Sponsor

University Health Network, Toronto (Other)

Overall Status

Completed

CT.gov ID

NCT02560909

Collaborator

(none)

Enrollment

Arms

Actual Duration (Months)

Study Details

Study Description

Brief Summary

Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for transplant patients, studies have shown that nonadjuvanted vaccine has poor immunogenicity. There are no studies that define the effect of adjuvanted vaccine in this population. The purpose of this study is to determine if a vaccination with FLUAD® results in improved immunogenicity as compared to standard vaccine in allo-HSCT recipients. Immunogenicity will be assessed by standard quantitative antibody titer assessments and using cell-mediated immunity measurements.

Condition or Disease	Intervention/Treatment	Phase
Transplantation Influenza Vaccines	Biological: FLUAD® influenza vaccine Biological: FLUVIRAL®	Phase 4

Detailed Description

The investigators plan to study the immunogenicity of two different types of the influenza vaccine in 240 allogeneic stem cell transplant patients during the 2015-2016 season. Patients will be randomized to receive either adjuvanted influenza vaccine or nonadjuvanted. Antibody titers will be evaluated by a standard hemagglutination inhibition assay. The investigators hypothesize that the patients who receive the adjuvanted influenza vaccine will reach significantly higher response to the vaccine. This study advances research on the prevention of serious viral infections in transplant recipients.

Results from this study have the potential to directly improve patient care. If the use of the adjuvanted influenza vaccine is successful, this strategy may lead to a significant reduction in burden of disease, hospitalizations, and long-term morbidity.

The co-administration of vaccine with an adjuvant is a potentially promising method of boosting immunogenicity. Two adjuvants have been used in influenza vaccines: AS03 and MF59. Both are oil-in-water emulsions. AS03 was used in the monovalent pandemic A/H1N1 vaccine in Canada and Europe. Adjuvanted vaccines have been studied in the hematopoietic stem cell transplant population with most studies done in using the AS03-adjuvanted pandemic vaccine. MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years old. MF59-adjuvanted vaccines have not been well studied in hematopoietic stem cell transplantation but could represent a significant advance if they show greater immunogenicity than the standard non-adjuvanted influenza vaccine. Both FLUAD® and the standard 2015-2016 nonadjuvanted vaccine will contain 15 microgram antigen from each strain and will be injected in a standard dose (0.5 mL) in the deltoid muscle by trained personnel.

Study Design

Study Type:

Interventional

Actual Enrollment :

73 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.

Actual Study Start Date :

Oct 1, 2015

Actual Primary Completion Date :

Feb 1, 2016

Actual Study Completion Date :

Aug 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.	Biological: FLUAD® influenza vaccine MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site. Other Names: MF59 adjuvanted vaccine
Active Comparator: Control The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.	Biological: FLUVIRAL® Standard 2015-2016 nonadjuvanted vaccine Other Names: Trivalent Influenza Vaccine

Arm

Intervention/Treatment

Experimental: Experimental

The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.

Biological: FLUAD® influenza vaccine

MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.

Other Names:

MF59 adjuvanted vaccine

Active Comparator: Control

The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.

Biological: FLUVIRAL®

Standard 2015-2016 nonadjuvanted vaccine

Other Names:

Trivalent Influenza Vaccine

Outcome Measures

Primary Outcome Measures

Rates of seroconversion [4 weeks from vaccination]
serological response with a four-fold or greater increase in HI antibody titers to an antigen

Secondary Outcome Measures

Rates of seroprotection [4 weeks from vaccination]
HIA titers of >=1:40
Rate of Local and systemic adverse events to vaccination [within 7 days of vaccination]
Number of participants with microbiologically-documented influenza infection [6 months from vaccination]
confirmed by direct fluorescent antibody, viral culture, or PCR

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥ 18
Greater than 3 months post-transplant
Allogeneic HSCT

Exclusion Criteria:

Has already received influenza vaccination for 2015-2016 season
Egg allergy
Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome)
Febrile illness in the past one week
Receipt of intravenous immunoglobulin (IVIG) in the past 30 days or planning to receive IVIG in the next 4 weeks
Unable to provide informed consent
Unable to comply with study protocol

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University Health Network, Toronto

Investigators

Principal Investigator: Deepali Kumar, MD, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Deepali Kumar, Physician, Transplant Infectious Diseases, University Health Network, Toronto

ClinicalTrials.gov Identifier:

NCT02560909

Other Study ID Numbers:

15-9503

First Posted:

Sep 25, 2015

Last Update Posted:

Apr 10, 2017

Last Verified:

Apr 1, 2017

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Influenza, Human

Vaccines

Study Results

No Results Posted as of Apr 10, 2017